These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

988 related items for PubMed ID: 10746426

  • 21. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
    Jiang Y, Li M, Xia W, Xing X, Yu W, Tian J, Meng X, Zhou X.
    Zhonghua Yi Xue Za Zhi; 2002 Sep 25; 82(18):1254-6. PubMed ID: 12425805
    [Abstract] [Full Text] [Related]

  • 22. Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
    Adachi JD.
    Can Fam Physician; 1998 Feb 25; 44():327-32. PubMed ID: 9512836
    [Abstract] [Full Text] [Related]

  • 23. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
    Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM, Fracture Intervention Trial Long-Term Extension Research Group.
    J Bone Miner Res; 2004 Aug 25; 19(8):1259-69. PubMed ID: 15231012
    [Abstract] [Full Text] [Related]

  • 24. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E, Bianchi G.
    Nephrol Dial Transplant; 2009 May 25; 24(5):1472-7. PubMed ID: 19075192
    [Abstract] [Full Text] [Related]

  • 25. Long-term predictions of the therapeutic equivalence of daily and less than daily alendronate dosing.
    Hernandez CJ, Beaupré GS, Marcus R, Carter DR.
    J Bone Miner Res; 2002 Sep 25; 17(9):1662-6. PubMed ID: 12211437
    [Abstract] [Full Text] [Related]

  • 26. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
    Stoch SA, Saag KG, Greenwald M, Sebba AI, Cohen S, Verbruggen N, Giezek H, West J, Schnitzer TJ.
    J Rheumatol; 2009 Aug 25; 36(8):1705-14. PubMed ID: 19487264
    [Abstract] [Full Text] [Related]

  • 27. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan 25; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 28. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK, Chadha M, Modi KD, Kumar KM, Mehrotra R, Sriram U.
    J Assoc Physicians India; 2008 Jun 25; 56():418-24. PubMed ID: 18822620
    [Abstract] [Full Text] [Related]

  • 29. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
    Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M.
    N Engl J Med; 1995 Nov 30; 333(22):1437-43. PubMed ID: 7477143
    [Abstract] [Full Text] [Related]

  • 30. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
    Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, Thompson DE, Karpf DB.
    Arch Intern Med; 1995 Nov 30; 157(22):2617-24. PubMed ID: 9531231
    [Abstract] [Full Text] [Related]

  • 31. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.
    Bone; 2006 Dec 30; 39(6):1268-75. PubMed ID: 16884968
    [Abstract] [Full Text] [Related]

  • 32. Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis.
    Chailurkit LO, Jongjaroenprasert W, Rungbunnapun S, Ongphiphadhanakul B, Sae-tung S, Rajatanavin R.
    J Bone Miner Metab; 2003 Dec 30; 21(6):421-7. PubMed ID: 14586800
    [Abstract] [Full Text] [Related]

  • 33. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate.
    Kendler D, Kung AW, Fuleihan Gel-H, González González JG, Gaines KA, Verbruggen N, Melton ME.
    Maturitas; 2004 Jul 15; 48(3):243-51. PubMed ID: 15207890
    [Abstract] [Full Text] [Related]

  • 34. An overview of the results of clinical trials with alendronate, a promising treatment of osteoporosis in postmenopausal women.
    Hirsch LJ, Pryor-Tillotson S.
    Ann Ital Med Int; 1995 Oct 15; 10 Suppl():22S-28S. PubMed ID: 8562261
    [Abstract] [Full Text] [Related]

  • 35. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD.
    J Bone Miner Res; 2009 Apr 15; 24(4):719-25. PubMed ID: 19049326
    [Abstract] [Full Text] [Related]

  • 36. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
    Miller PD.
    Clin Ther; 2005 Apr 15; 27(4):361-76. PubMed ID: 15922811
    [Abstract] [Full Text] [Related]

  • 37. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.
    Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D.
    Arthritis Rheum; 1999 Jun 15; 42(6):1246-54. PubMed ID: 10366118
    [Abstract] [Full Text] [Related]

  • 38. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis.
    Rossini M, Gatti D, Zamberlan N, Braga V, Dorizzi R, Adami S.
    J Bone Miner Res; 1994 Nov 15; 9(11):1833-7. PubMed ID: 7863833
    [Abstract] [Full Text] [Related]

  • 39. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH.
    J Bone Miner Res; 2005 Nov 15; 20(11):1905-11. PubMed ID: 16234962
    [Abstract] [Full Text] [Related]

  • 40. [The effect of a one-year alendronate therapy on postmenopausal osteoporosis. (Results in Hungary of an international multicenter clinical study)].
    Bettembuk P, Balogh A.
    Orv Hetil; 1999 Dec 12; 140(50):2799-803. PubMed ID: 10647267
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 50.